JP2019509055A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509055A5
JP2019509055A5 JP2018555841A JP2018555841A JP2019509055A5 JP 2019509055 A5 JP2019509055 A5 JP 2019509055A5 JP 2018555841 A JP2018555841 A JP 2018555841A JP 2018555841 A JP2018555841 A JP 2018555841A JP 2019509055 A5 JP2019509055 A5 JP 2019509055A5
Authority
JP
Japan
Prior art keywords
cancer
miac
abm2
abm3
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018555841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509055A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013512 external-priority patent/WO2017124002A1/en
Publication of JP2019509055A publication Critical patent/JP2019509055A/ja
Publication of JP2019509055A5 publication Critical patent/JP2019509055A5/ja
Withdrawn legal-status Critical Current

Links

JP2018555841A 2016-01-13 2017-01-13 多特異性免疫調節抗原結合構築物 Withdrawn JP2019509055A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662278359P 2016-01-13 2016-01-13
US62/278,359 2016-01-13
US201662361842P 2016-07-13 2016-07-13
US62/361,842 2016-07-13
PCT/US2017/013512 WO2017124002A1 (en) 2016-01-13 2017-01-13 Multispecific immunomodulatory antigen-binding constructs

Publications (2)

Publication Number Publication Date
JP2019509055A JP2019509055A (ja) 2019-04-04
JP2019509055A5 true JP2019509055A5 (2) 2020-02-27

Family

ID=59311459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555841A Withdrawn JP2019509055A (ja) 2016-01-13 2017-01-13 多特異性免疫調節抗原結合構築物

Country Status (9)

Country Link
US (1) US20190031785A1 (2)
EP (1) EP3402519A4 (2)
JP (1) JP2019509055A (2)
CN (1) CN109562162A (2)
AU (1) AU2017207480A1 (2)
BR (1) BR112018014368A2 (2)
CA (1) CA3011535A1 (2)
MA (1) MA43874A (2)
WO (1) WO2017124002A1 (2)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US20200231679A1 (en) * 2017-08-23 2020-07-23 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3740505A1 (en) * 2018-01-16 2020-11-25 Lakepharma Inc. Bispecific antibody that binds cd3 and another target
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CA3089230A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
AU2019271263A1 (en) * 2018-05-16 2020-12-03 Dragonfly Therapeutics, Inc. Protein binding NKG2D, CD16 and a fibroblast activation protein
CA3099308A1 (en) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020227431A1 (en) * 2019-05-06 2020-11-12 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
CN112409484B (zh) * 2019-08-22 2023-03-21 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
US20230128499A1 (en) 2020-03-27 2023-04-27 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
JP2023532279A (ja) * 2020-06-26 2023-07-27 ソレント・セラピューティクス・インコーポレイテッド 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022200478A1 (en) * 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
WO2022262678A1 (zh) * 2021-06-15 2022-12-22 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
CA3216098A1 (en) * 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
US20240327543A1 (en) * 2021-08-02 2024-10-03 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
KR20100058509A (ko) * 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
WO2013048243A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CN104185642A (zh) * 2011-12-27 2014-12-03 财团法人生物技术开发中心 轻链桥连的双特异性抗体
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs

Similar Documents

Publication Publication Date Title
JP2019509055A5 (2)
CN110914306B (zh) 检查点抑制物双特异性抗体
RU2445319C2 (ru) Моноклональные антитела к клаудину-18 для лечения рака
ES2776706T3 (es) Anticuerpos contra CD3 humanizados o quiméricos
JP2018503399A5 (2)
US11913025B2 (en) Antigen-specific T cells and uses thereof
JP2025023994A (ja) バイパラトピックＦＲ－α抗体及びイムノコンジュゲート
IL273424B2 (en) Novel bispecific cd3/cd19 polypeptide complexes
JP2020500540A5 (2)
EP3774921A1 (en) Antibody variable domains targeting dll3, and use thereof
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2018507188A5 (2)
JP2013502913A5 (2)
EP3177646A1 (en) Cd3 binding domain
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2013545455A5 (2)
TR201807202T4 (tr) CD70 antikorları.
JP2021520201A5 (2)
CN106414494A (zh) 具有促凋亡活性的人IgG1衍生的抗体
JP2025186381A (ja) Ｃｄ１３７結合分子及びその使用
US20250188166A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
JP2023501379A (ja) ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
TW201927819A (zh) 雙專一性抗體及製造與使用其的方法
US20260055173A1 (en) Bispecific antibody and application thereof
JP7730432B2 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用